c-Met and Other Cell Surface Molecules: Interaction, Activation and Functional Consequences
暂无分享,去创建一个
[1] A. Can,et al. Reciprocal Activating Crosstalk between c-Met and Caveolin 1 Promotes Invasive Phenotype in Hepatocellular Carcinoma , 2014, PloS one.
[2] P. Comoglio,et al. Met-mediated Resistance to Egfr Inhibitors: an Old Liaison Rooted in Colorectal Cancer Stem Cells Egfr Is a Therapeutic Target in Colorectal Cancer Met Activation Is a Mechanism of Resistance to Egfr Inhibition , 2022 .
[3] D. Parums,et al. Current status of targeted therapy in non-small cell lung cancer. , 2014, Drugs of today.
[4] P. Mukherjee,et al. MUC1: a multifaceted oncoprotein with a key role in cancer progression. , 2014, Trends in molecular medicine.
[5] J. Ivaska,et al. Tensin-4-Dependent MET Stabilization Is Essential for Survival and Proliferation in Carcinoma Cells , 2014, Developmental cell.
[6] T. Stinchcombe. Novel agents in development for advanced non-small cell lung cancer , 2014, Therapeutic advances in medical oncology.
[7] P. Parker,et al. Receptor tyrosine kinase c-Met controls the cytoskeleton from different endosomes via different pathways , 2014, Nature Communications.
[8] Wanlu Du,et al. Targeting c-Met Receptor Overcomes TRAIL-Resistance in Brain Tumors , 2014, PloS one.
[9] R. Jarvis,et al. Shedding of c-Met is regulated by crosstalk between a G-protein coupled receptor and the EGF receptor and is mediated by a TIMP-3 sensitive metalloproteinase , 2014, Journal of Cell Science.
[10] B. Geiger,et al. The integrin adhesome: from genes and proteins to human disease , 2014, Nature Reviews Molecular Cell Biology.
[11] R. Markwald,et al. Overexpression of c-Met and CD44v6 Receptors Contributes to Autocrine TGF-β1 Signaling in Interstitial Lung Disease* , 2014, The Journal of Biological Chemistry.
[12] R. Govindan,et al. Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Ryan J. Jacobs,et al. Alternative Signaling Pathways as Potential Therapeutic Targets for Overcoming EGFR and c-Met Inhibitor Resistance in Non-Small Cell Lung Cancer , 2013, PloS one.
[14] Jianing Zhang,et al. Synergistic inhibition of cell migration by tetraspanin CD82 and gangliosides occurs via the EGFR or cMet-activated Pl3K/Akt signalling pathway. , 2013, The international journal of biochemistry & cell biology.
[15] F. Ciardiello,et al. Increased TGF-α as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR–MET Interaction and Activation of MET Signaling in Colon Cancer Cells , 2013, Clinical Cancer Research.
[16] D. Nguyen,et al. EGF receptor activates MET through MAPK to enhance non-small cell lung carcinoma invasion and brain metastasis. , 2013, Cancer research.
[17] M. Williamson,et al. Function of mutant and wild-type plexinB1 in prostate cancer cells , 2013, The Prostate.
[18] G. V. Vande Woude,et al. Strengthening Context-Dependent Anticancer Effects on Non–Small Cell Lung Carcinoma by Inhibition of Both MET and EGFR , 2013, Molecular Cancer Therapeutics.
[19] C. Croce,et al. Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2 , 2013, Proceedings of the National Academy of Sciences.
[20] Angeliki Mela,et al. CD82 Blocks cMet Activation and Overcomes Hepatocyte Growth Factor Effects on Oligodendrocyte Precursor Differentiation , 2013, The Journal of Neuroscience.
[21] M. Kuwano,et al. Sorting nexin 2‐mediated membrane trafficking of c‐Met contributes to sensitivity of molecular‐targeted drugs , 2013, Cancer science.
[22] David Koschut,et al. Internalization of Met Requires the Co-Receptor CD44v6 and Its Link to ERM Proteins , 2013, PloS one.
[23] Caicun Zhou,et al. Association of integrin beta1 and c-MET in mediating EGFR TKI gefitinib resistance in non-small cell lung cancer , 2013, Cancer Cell International.
[24] J. Satagopan,et al. β4 Integrin signaling induces expansion of prostate tumor progenitors. , 2013, The Journal of clinical investigation.
[25] J. Soong,et al. Plexin B1 inhibits MET through direct association and regulates Shp2 expression in melanocytes , 2013, Journal of Cell Science.
[26] R. Salgia,et al. Critical Role of S1PR1 and Integrin β4 in HGF/c-Met-mediated Increases in Vascular Integrity , 2012, The Journal of Biological Chemistry.
[27] Benjamin G. Bitler,et al. MUC1 Drives c-Met–Dependent Migration and Scattering , 2012, Molecular Cancer Research.
[28] C. Korch,et al. Cooperative interaction of MUC1 with the HGF/c-Met pathway during hepatocarcinogenesis , 2012, Molecular Cancer.
[29] Tianliang Sun,et al. Grb2 mediates semaphorin-4D-dependent RhoA inactivation , 2012, Journal of Cell Science.
[30] S. Goodman,et al. Integrins as therapeutic targets. , 2012, Trends in pharmacological sciences.
[31] J. Norman,et al. Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion , 2012, Oncogene.
[32] L. Cingolani,et al. Tetraspanins: Interactions and interplay with integrins. , 2012, The international journal of biochemistry & cell biology.
[33] M. Tremblay,et al. Protein-tyrosine Phosphatase 1B Modulates Early Endosome Fusion and Trafficking of Met and Epidermal Growth Factor Receptors* , 2011, The Journal of Biological Chemistry.
[34] J. Heino,et al. Cooperation between integrins and growth factor receptors in signaling and endocytosis. , 2011, Annual review of cell and developmental biology.
[35] L. Sequist,et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] I. Okamoto,et al. Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification , 2011, British Journal of Cancer.
[37] G. Pace,et al. c-Met recruits ICAM-1 as a coreceptor to compensate for the loss of CD44 in Cd44 null mice , 2011, Molecular biology of the cell.
[38] V. Calléja,et al. A direct role for Met endocytosis in tumorigenesis , 2011, Nature Cell Biology.
[39] Morag Park,et al. GGA3 functions as a switch to promote Met receptor recycling, essential for sustained ERK and cell migration. , 2011, Developmental cell.
[40] Xianghong Jing,et al. Functional and biochemical studies of CD9 in fibrosarcoma cell line , 2011, Molecular and Cellular Biochemistry.
[41] Stephen L. Abrams,et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health , 2011, Oncotarget.
[42] A. Dulak,et al. HGF-independent Potentiation of EGFR Action by c-Met , 2011, Oncogene.
[43] L. Trusolino,et al. MET signalling: principles and functions in development, organ regeneration and cancer , 2010, Nature Reviews Molecular Cell Biology.
[44] E. Lengyel,et al. Ligand independent activation of c-Met by fibronectin and α5β1-integrin regulates ovarian cancer invasion and metastasis , 2010, Oncogene.
[45] L. Trusolino,et al. The Tetraspanin CD151 Is Required for Met-dependent Signaling and Tumor Cell Growth* , 2010, The Journal of Biological Chemistry.
[46] Atsushi Kumanogoh,et al. Roles of Sema4D and Plexin-B1 in tumor progression , 2010, Molecular Cancer.
[47] G. V. Vande Woude,et al. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. , 2010, Cancer research.
[48] L. Leng,et al. c-Met and Its Ligand Hepatocyte Growth Factor/Scatter Factor Regulate Mature B Cell Survival in a Pathway Induced by CD74 , 2010, The Journal of Immunology.
[49] H. Kerl,et al. HGF-promoted motility in primary human melanocytes depends on CD44v6 regulated via NF-kappa B, Egr-1, and C/EBP-beta. , 2010, The Journal of investigative dermatology.
[50] Morag Park,et al. Dorsal Ruffle Microdomains Potentiate Met Receptor Tyrosine Kinase Signaling and Down-regulation* , 2010, The Journal of Biological Chemistry.
[51] M. Williamson,et al. Plexin B1 suppresses c-Met in melanoma: a role for plexin B1 as a tumor-suppressor protein through regulation of c-Met. , 2010, The Journal of investigative dermatology.
[52] R. Markwald,et al. Stromal Hyaluronan Interaction with Epithelial CD44 Variants Promotes Prostate Cancer Invasiveness by Augmenting Expression and Function of Hepatocyte Growth Factor and Androgen Receptor* , 2010, The Journal of Biological Chemistry.
[53] Luca Toschi,et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. , 2010, Cancer cell.
[54] F. Marshall,et al. Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells , 2010, Molecular Cancer.
[55] J. Norman,et al. Mutant p53 Drives Invasion by Promoting Integrin Recycling , 2009, Cell.
[56] Morag Park,et al. Crosstalk in Met receptor oncogenesis. , 2009, Trends in cell biology.
[57] S. Pietronave,et al. Deletion of the ectodomain unleashes the transforming, invasive, and tumorigenic potential of the MET oncogene , 2009, Cancer science.
[58] S. Qin,et al. Coordinate integrin and c-Met signaling regulate Wnt gene expression during epithelial morphogenesis , 2009, Development.
[59] K. Nakashiro,et al. CD151 regulates HGF-stimulated morphogenesis of human breast cancer cells. , 2009, Biochemical and biophysical research communications.
[60] M. Tremblay,et al. Regulation of the Met Receptor-tyrosine Kinase by the Protein-tyrosine Phosphatase 1B and T-cell Phosphatase* , 2008, Journal of Biological Chemistry.
[61] Y. Yatabe,et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. , 2008, Cancer research.
[62] N. Rosen,et al. HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells , 2008, Molecular Cancer Therapeutics.
[63] Andrew J. Lindsay,et al. Rab-coupling protein coordinates recycling of α5β1 integrin and EGFR1 to promote cell migration in 3D microenvironments , 2008, The Journal of cell biology.
[64] P. Singh,et al. Phosphorylation of MUC1 by Met Modulates Interaction with p53 and MMP1 Expression* , 2008, Journal of Biological Chemistry.
[65] P. Parker,et al. Receptor trafficking controls weak signal delivery: a strategy used by c-Met for STAT3 nuclear accumulation , 2008, The Journal of cell biology.
[66] Deborah S. Barkauskas,et al. Dual MET–EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer , 2008, British Journal of Cancer.
[67] I. Shimomura,et al. The tetraspanin CD9 modulates epidermal growth factor receptor signaling in cancer cells , 2008, Journal of cellular physiology.
[68] S. Ethier,et al. Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells. , 2008, Cancer research.
[69] M. Zutter,et al. Crosstalk between the alpha2beta1 integrin and c-met/HGF-R regulates innate immunity. , 2008, Blood.
[70] K. Carraway,et al. Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. , 2008, Cancer research.
[71] S. Offermanns,et al. ErbB-2 and Met Reciprocally Regulate Cellular Signaling via Plexin-B1* , 2008, Journal of Biological Chemistry.
[72] Steven P Gygi,et al. Signaling networks assembled by oncogenic EGFR and c-Met , 2008, Proceedings of the National Academy of Sciences.
[73] E. Rosen,et al. Transcription-Dependent Epidermal Growth Factor Receptor Activation by Hepatocyte Growth Factor , 2008, Molecular Cancer Research.
[74] Matthias Buck,et al. Binding of Rac1, Rnd1, and RhoD to a Novel Rho GTPase Interaction Motif Destabilizes Dimerization of the Plexin-B1 Effector Domain* , 2007, Journal of Biological Chemistry.
[75] K. Shirasuna,et al. Regulation of c‐Met signaling by the tetraspanin KAI‐1/CD82 affects cancer cell migration , 2007, International journal of cancer.
[76] R. Salgia,et al. CD44 Regulates Hepatocyte Growth Factor-mediated Vascular Integrity , 2007, Journal of Biological Chemistry.
[77] G. Aramuni,et al. Haploinsufficiency of c-Met in cd44−/− Mice Identifies a Collaboration of CD44 and c-Met In Vivo , 2007, Molecular and Cellular Biology.
[78] G. Basso,et al. Hepatocyte Growth Factor Receptor c-MET Is Associated with FAS and When Activated Enhances Drug-induced Apoptosis in Pediatric B Acute Lymphoblastic Leukemia with TEL-AML1 Translocation* , 2007, Journal of Biological Chemistry.
[79] G. Michalopoulos,et al. Lack of Fas antagonism by Met in human fatty liver disease , 2007, Nature Medicine.
[80] Forest M White,et al. Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma , 2007, Proceedings of the National Academy of Sciences.
[81] L. Elferink,et al. Specific Grb2-mediated Interactions Regulate Clathrin-dependent Endocytosis of the cMet-tyrosine Kinase* , 2007, Journal of Biological Chemistry.
[82] Joon-Oh Park,et al. MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.
[83] Ke-Ping Xu,et al. Cross talk between c-Met and epidermal growth factor receptor during retinal pigment epithelial wound healing. , 2007, Investigative ophthalmology & visual science.
[84] H. Moses,et al. Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells , 2007, Cancer biology & therapy.
[85] K. Handa,et al. Ganglioside GM2-Tetraspanin CD82 Complex Inhibits Met and Its Cross-talk with Integrins, Providing a Basis for Control of Cell Motility through Glycosynapse* , 2007, Journal of Biological Chemistry.
[86] Y. Fukami,et al. Tyrosine phosphorylation of p145met mediated by EGFR and Src is required for serum-independent survival of human bladder carcinoma cells , 2006, Journal of Cell Science.
[87] P. Herrlich,et al. Hepatocyte growth factor-induced Ras activation requires ERM proteins linked to both CD44v6 and F-actin. , 2006, Molecular biology of the cell.
[88] Lee M Ellis,et al. Regulatory role of c-Met in insulin-like growth factor-I receptor–mediated migration and invasion of human pancreatic carcinoma cells , 2006, Molecular Cancer Therapeutics.
[89] G. Christofori. New signals from the invasive front , 2006, Nature.
[90] C. Miranti,et al. Tetraspanin KAI1/CD82 suppresses invasion by inhibiting integrin-dependent crosstalk with c-Met receptor and Src kinases , 2006, Oncogene.
[91] Toshikazu Nakamura,et al. Contact Inhibition of Hepatocyte Growth Regulated by Functional Association of the c-Met/Hepatocyte Growth Factor Receptor and LAR Protein-tyrosine Phosphatase* , 2006, Journal of Biological Chemistry.
[92] Shu-yi Chen,et al. Crosstalk between hepatocyte growth factor and integrin signaling pathways. , 2006, Journal of biomedical science.
[93] L. Trusolino,et al. Beta4 integrin is a transforming molecule that unleashes Met tyrosine kinase tumorigenesis. , 2005, Cancer research.
[94] K. Nakashiro,et al. CD151 forms a functional complex with c-Met in human salivary gland cancer cells. , 2005, Biochemical and biophysical research communications.
[95] H. Brady,et al. cMet and Fas Receptor Interaction Inhibits Death-Inducing Signaling Complex Formation in Endothelial Cells , 2005, Hypertension.
[96] P. Comoglio,et al. Sema4D induces angiogenesis through Met recruitment by Plexin B1. , 2005, Blood.
[97] J. Salles,et al. A Novel Role for Gab1 and SHP2 in Epidermal Growth Factor-induced Ras Activation* , 2005, Journal of Biological Chemistry.
[98] P. Parker,et al. PKC controls HGF‐dependent c‐Met traffic, signalling and cell migration , 2004, The EMBO journal.
[99] Motonao Nakamura,et al. MUC20 Suppresses the Hepatocyte Growth Factor-Induced Grb2-Ras Pathway by Binding to a Multifunctional Docking Site of Met , 2004, Molecular and Cellular Biology.
[100] L. Pelkmans,et al. Not just a sink: endosomes in control of signal transduction. , 2004, Current opinion in cell biology.
[101] A. Mercurio,et al. The Met Receptor and α6β4 Integrin Can Function Independently to Promote Carcinoma Invasion* , 2004, Journal of Biological Chemistry.
[102] P. Comoglio,et al. Interplay between scatter factor receptors and B plexins controls invasive growth , 2004, Oncogene.
[103] Giorgio F. Gilestro,et al. Plexin‐B3 is a functional receptor for semaphorin 5A , 2004, EMBO reports.
[104] Christian Wiesmann,et al. Crystal structure of the HGF β‐chain in complex with the Sema domain of the Met receptor , 2004, The EMBO journal.
[105] W. Birchmeier,et al. Met, metastasis, motility and more , 2003, Nature Reviews Molecular Cell Biology.
[106] G. V. Vande Woude,et al. Endosomal dynamics of Met determine signaling output. , 2003, Molecular biology of the cell.
[107] N. Tonks,et al. Hepatocyte Growth Factor Receptor Tyrosine Kinase Met Is a Substrate of the Receptor Protein-tyrosine Phosphatase DEP-1* , 2003, The Journal of Biological Chemistry.
[108] J. Sleeman,et al. CD44 is required for two consecutive steps in HGF/c-Met signaling. , 2002, Genes & development.
[109] Giorgio F. Gilestro,et al. The Semaphorin 4D receptor controls invasive growth by coupling with Met , 2002, Nature Cell Biology.
[110] B. Vandenbunder,et al. Hepatocyte growth factor/scatter factor activates the ETS1 transcription factor by a RAS-RAF-MEK-ERK signaling pathway , 2002, Oncogene.
[111] L. Trusolino,et al. Scatter-factor and semaphorin receptors: cell signalling for invasive growth , 2002, Nature Reviews Cancer.
[112] Giorgio F. Gilestro,et al. The endophilin–CIN85–Cbl complex mediates ligand-dependent downregulation of c-Met , 2002, Nature.
[113] A. Bell,et al. A mechanism of cell survival: sequestration of Fas by the HGF receptor Met. , 2002, Molecular cell.
[114] R. Jove,et al. Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis , 2002, Oncogene.
[115] L. Trusolino,et al. A Signaling Adapter Function for α6β4 Integrin in the Control of HGF-Dependent Invasive Growth , 2001, Cell.
[116] E. Rosen,et al. The Multisubstrate Adapter Gab1 Regulates Hepatocyte Growth Factor (Scatter Factor)–c-Met Signaling for Cell Survival and DNA Repair , 2001, Molecular and Cellular Biology.
[117] G. Woude,et al. Down-regulation of MET, the receptor for hepatocyte growth factor , 2001, Oncogene.
[118] Hailan Hu,et al. Plexin-B semaphorin receptors interact directly with active Rac and regulate the actin cytoskeleton by activating Rho , 2001, Current Biology.
[119] G. V. Vande Woude,et al. Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[120] D. Kamikura,et al. A switch from p130Cas/Crk to Gab1/Crk signaling correlates with anchorage independent growth and JNK activation in cells transformed by the Met receptor oncoprotein , 2000, Oncogene.
[121] D. Robinson,et al. The protein tyrosine kinase family of the human genome , 2000, Oncogene.
[122] C. Maroun,et al. The Tyrosine Phosphatase SHP-2 Is Required for Sustained Activation of Extracellular Signal-Regulated Kinase and Epithelial Morphogenesis Downstream from the Met Receptor Tyrosine Kinase , 2000, Molecular and Cellular Biology.
[123] M. Naujokas,et al. Identification of an Atypical Grb2 Carboxyl-terminal SH3 Domain Binding Site in Gab Docking Proteins Reveals Grb2-dependent and -independent Recruitment of Gab1 to Receptor Tyrosine Kinases* , 2000, The Journal of Biological Chemistry.
[124] W. Birchmeier,et al. Essential Role of Gab1 for Signaling by the C-Met Receptor in Vivo , 2000, The Journal of cell biology.
[125] W. Birchmeier,et al. Coupling of Gab1 to C-Met, Grb2, and Shp2 Mediates Biological Responses , 2000, The Journal of cell biology.
[126] M. Stella,et al. Cross-talk between the proto-oncogenes Met and Ron , 2000, Oncogene.
[127] D. Stolz,et al. Cross-talk between Epidermal Growth Factor Receptor and c-Met Signal Pathways in Transformed Cells* , 2000, The Journal of Biological Chemistry.
[128] P. Comoglio,et al. Sustained recruitment of phospholipase C-γ to Gab1 is required for HGF-induced branching tubulogenesis , 2000, Oncogene.
[129] K. Vuori,et al. Met-induced JNK activation is mediated by the adapter protein Crk and correlates with the Gab1 – Crk signaling complex formation , 1999, Oncogene.
[130] L. Buday,et al. Phosphatidylinositol 3-kinase contributes to Erk1/Erk2 MAP kinase activation associated with hepatocyte growth factor-induced cell scattering. , 1999, Cellular signalling.
[131] M. Poo,et al. Plexins Are a Large Family of Receptors for Transmembrane, Secreted, and GPI-Anchored Semaphorins in Vertebrates , 1999, Cell.
[132] E. Gherardi,et al. Heparan Sulfate-modified CD44 Promotes Hepatocyte Growth Factor/Scatter Factor-induced Signal Transduction through the Receptor Tyrosine Kinase c-Met* , 1999, The Journal of Biological Chemistry.
[133] Morag Park,et al. The Gab1 PH Domain Is Required for Localization of Gab1 at Sites of Cell-Cell Contact and Epithelial Morphogenesis Downstream from the Met Receptor Tyrosine Kinase , 1999, Molecular and Cellular Biology.
[134] J. Downward,et al. Phosphoinositide 3-Kinase Induces Scattering and Tubulogenesis in Epithelial Cells through a Novel Pathway* , 1998, The Journal of Biological Chemistry.
[135] A. Bardelli,et al. Induction of epithelial tubules by growth factor HGF depends on the STAT pathway , 1998, Nature.
[136] Alexis Gautreau,et al. Ezrin Is an Effector of Hepatocyte Growth Factor–mediated Migration and Morphogenesis in Epithelial Cells , 1997, The Journal of cell biology.
[137] S. Ōmura,et al. Degradation of the Met tyrosine kinase receptor by the ubiquitin-proteasome pathway , 1997, Molecular and cellular biology.
[138] W. Birchmeier,et al. Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis , 1996, Nature.
[139] J. Bishop,et al. Cellular adherence elicits ligand-independent activation of the Met cell-surface receptor. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[140] M. Glimcher,et al. Receptor-Ligand Interaction Between CD44 and Osteopontin (Eta-1) , 1996, Science.
[141] A. Bardelli,et al. The motogenic and mitogenic responses to HGF are amplified by the Shc adaptor protein. , 1995, Oncogene.
[142] K.,et al. The motility signal of scatter factor/hepatocyte growth factor mediated through the receptor tyrosine kinase met requires intracellular action of Ras. , 1994, The Journal of biological chemistry.
[143] A. Bardelli,et al. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family , 1994, Cell.
[144] J. Mendelsohn,et al. Consumption of EGF by A431 cells: evidence for receptor recycling , 1993, The Journal of cell biology.
[145] Richard O. Hynes,et al. Integrins: Versatility, modulation, and signaling in cell adhesion , 1992, Cell.
[146] C. Cooper,et al. Tyrosine kinase receptor indistinguishable from the c-met protein , 1989, Nature.
[147] M. Braun,et al. Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[148] Michael Stoker,et al. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility , 1987, Nature.
[149] Y. Oshika,et al. P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo. , 1996, British Journal of Cancer.
[150] T. Pellinen,et al. Negative regulation of EGFR signalling through integrin-alpha1beta1-mediated activation of protein tyrosine phosphatase TCPTP. , 2005, Nature cell biology.
[151] Jacqueline Murray,et al. Novel hepatocyte growth factor (HGF) binding domains on fibronectin and vitronectin coordinate a distinct and amplified Met-integrin induced signalling pathway in endothelial cells. , 2005, BMC Cell Biology.
[152] L. Trusolino,et al. A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth. , 2001, Cell.
[153] L. Vician,et al. The Urokinase Plasminogen Activator Receptor (UPAR) Is Preferentially Induced by Nerve Growth Factor in PC12 Pheochromocytoma Cells and Is Required for NGF-Driven Differentiation , 2000, Journal of Neuroscience.
[154] P. P. Di Fiore,et al. Endocytosis and mitogenic signaling. , 1999, Current opinion in cell biology.